Revenue Insights: Pharming Group N.V. and Supernus Pharmaceuticals, Inc. Performance Compared

Pharmaceutical Revenue Growth: Pharming vs. Supernus

__timestampPharming Group N.V.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 201425762439122045000
Thursday, January 1, 201511838278144427000
Friday, January 1, 201616693660215003000
Sunday, January 1, 2017107517335302238000
Monday, January 1, 2018154575611408897000
Tuesday, January 1, 2019189333721392755000
Wednesday, January 1, 2020228394666520397000
Friday, January 1, 2021189853037579775000
Saturday, January 1, 2022205622000667238000
Sunday, January 1, 2023245316000607521000
Loading chart...

Infusing magic into the data realm

Revenue Growth in the Pharmaceutical Sector: A Comparative Analysis

In the ever-evolving pharmaceutical industry, understanding revenue trends is crucial for investors and stakeholders. This analysis focuses on the revenue performance of Pharming Group N.V. and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Supernus Pharmaceuticals consistently outperformed Pharming Group, with revenues peaking at approximately $667 million in 2022, marking a 447% increase from 2014. In contrast, Pharming Group's revenue grew by 852% over the same period, reaching around $245 million in 2023.

Key Insights

  • 2014-2023 Growth: Pharming Group's revenue surged by over 8.5 times, while Supernus Pharmaceuticals saw a 4.5-fold increase.
  • Peak Performance: Supernus Pharmaceuticals achieved its highest revenue in 2022, while Pharming Group peaked in 2023.

These insights highlight the dynamic nature of the pharmaceutical sector and the varying growth trajectories of its players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025